Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Q-Line BiotechNSE:QLINE -1.12%14 Debt-to-Equity is 0.88 as of Mar. 2025, which is 47% above its 10-year median of 0.60. GuruFocus rates NSE:QLINE with a GF Score™ of 14/100. The stock has 2 warning signs investors should review. Among 704 Medical Devices & Instruments companies, Q-Line Biotech ranks worse than 81.82% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Q-Line Biotech's Debt-to-Equity or its related term are showing as below:
NSE:QLINE'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.58 Med: 0.6 Max: 0.88
Current: 0.88
During the past 3 years, the highest Debt-to-Equity Ratio of Q-Line Biotech was 0.88. The lowest was 0.58. And the median was 0.60.
NSE:QLINE's Debt-to-Equity is ranked worse than 81.82% of 704
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs NSE:QLINE: 0.88
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Q-Line Biotech Debt-to-Equity Related Terms
Q-Line Biotech Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Q-Line Biotech's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Q-Line Biotech Debt-to-Equity Chart
Q-Line Biotech Annual Data
Trend
Mar23
Mar24
Mar25
Debt-to-Equity
0.58
0.60
0.88
Q-Line Biotech Semi-Annual Data
Mar23
Mar24
Mar25
Debt-to-Equity
0.58
0.60
0.88
NSE:QLINE vs ABT, SYK, MDT: Debt-to-Equity Comparison
For the Medical Devices subindustry, Q-Line Biotech's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Q-Line Biotech Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Q-Line Biotech's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Q-Line Biotech's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Q-Line Biotech (NSE:QLINE) has a Debt-to-Equity of 0.88 as of Mar. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Q-Line Biotech and its competitors. This is 47% above median its historical median of 0.60. Over the past decade, Q-Line Biotech's Debt-to-Equity has ranged from 0.58 to 0.88. According to the industry distribution chart, Q-Line Biotech ranks #576 out of 704 companies in the Medical Devices & Instruments industry, placing it in the top 81.8%.
Is Q-Line Biotech's Debt-to-Equity too high?
Q-Line Biotech's current Debt-to-Equity of 0.88 is 47% above median its 10-year median of 0.60. Over the past 10 years, this metric has ranged from a low of 0.58 to a high of 0.88. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Q-Line Biotech's value of 0.88 is 282.6% above this industry median. Based on the distribution chart, Q-Line Biotech ranks #576 out of 704 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Q-Line Biotech has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Q-Line Biotech's Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Q-Line Biotech ranks #576 out of 704 companies for Debt-to-Equity. This places Q-Line Biotech in the lower half of its industry. The industry median Debt-to-Equity is 0.23. Q-Line Biotech's value of 0.88 is 282.6% above this benchmark. Historically, Q-Line Biotech's own Debt-to-Equity has ranged from 0.58 to 0.88 over the past decade. While the company's 10-year median is 0.60 vs. the industry median of 0.23, Q-Line Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Q-Line Biotech's current Debt-to-Equity of 0.88 is 282.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Q-Line Biotech and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Q-Line Biotech's current Debt-to-Equity is 0.88, which is 47% above median its own 10-year median of 0.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-Line Biotech stock overvalued right now?
Q-Line Biotech (NSE:QLINE) has a current Debt-to-Equity of 0.88. The current Debt-to-Equity is 0.88, which is 47% above median its 10-year median of 0.60 and 282.6% above the Medical Devices & Instruments industry median of 0.23. Q-Line Biotech's overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Q-Line Biotech (NSE:QLINE), the current Debt-to-Equity is 0.88 as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Q-Line Biotech Ltd is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs directly or through its distributors majorly to diagnostic service providers, hospitals and medical colleges. It is engaged in Manufacturing and Trading into Biochemistry Regnant, Instruments and Consumables. The majority of revenue is derived from the Manufacturing segment.
14GF Score
Get the complete analysis for NSE:QLINE
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:QLINE has been successfully added to your 
